Bridging the Gap Between Our Understanding of AML Pathogenesis and the Development of
Targeted Therapies Montreh Tavakkoli Submitted in partial fulfillment of the requirements for the …

Page 1 AML in the Molecular Age: From Biology to Clinical Management Celalettin Ustun
and Lucy A. Godley Edited by Printed Edition of the Special Issue Published in JCM www.mdpi.com/journal/jcm …

Acute myeloid leukemia (AML) is the most frequent leukemia in adults and presents a very
high incidence all over the world. The most important aberrations involve mutations and …

Conclusion We expect that the future of AML therapy will incorporate well-designed and
target-specific molecules into current treatment strategies in an individualized manner …

Despite modest improvements in survival over the last several decades, the treatment of
AML continues to present a formidable challenge. Most patients are elderly, and these …

Background: Defects in DNA repair pathways are causal factors for a plethora of solid
tumours, but are only just beginning to be explored in haematological malignancies …

OBJECTIVES While cancer registries such as SEER currently serve as the largest source of
cancer epidemiology, recent research (Cogle, et al., 2012) has suggested that these …

To identify genes whose expression correlated with biological features of therapy-related
AML (t-AML), we analyzed the expression profiles of de novo AML t (9; 11) and t-AML t (9; …

The standard approaches to the treatment of acute myeloid leukemia (AML) have been
predominantly based on cytarabine and anthracyclines. Yet, the outcomes associated with …

Acute myeloid leukemia (AML) is a rapidly growing form of cancer in which the bone marrow
massively overproduces immature blast cells, preventing production of normal blood cells …